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For many years early arthritis clinics have been promoted as a means of improving long-
term outcome for patients (1), the logic being that early therapy minimises structural 
damage, (which correlates with longer term functional loss), induced by inflammation both 
locally and systemically (2). Furthermore, there is the long-term belief in the, at least 
theoretical, window of opportunity whereby early intervention permits a qualitatively 
better outcome than the same intervention applied at a later date(1). A recent focus on 
individuals “at risk” has led to the realisation that multiple pathological mechanisms are 
taking place prior to clinical arthritis, for example objective evidence of sub-clinical 
inflammation on sensitive imaging (3-5)or immunological abnormalities in T-cell subsets (6). 
  
These data led to the maxims that “the earlier the better” and “never too soon to treat RA”. 
Indeed, expert opinion led EULAR to the recommendation that patients should start 
treatment within 6 weeks after “any joint swelling associated with pain or stiffness” (7). 
Using extensive inception cohort data from Leiden and France Niemantsverdriet et al (8) 
have produced the best evidence so far to address this question. Their findings show in a 
meta-analysis of two cohorts that a time to encounter (TtE) of ≤6weeks was 1.7 times more 
likely to achieve sustained drug-free remission (SDFR) compared to both 7-11weeks TtE (HR 
1.69; 95% CI 1.10-2.57; p=0.02) and ≥12weeks TtE (HR1.67; 95% CI 1.08-2.58; p=0.02). 
Leiden’s results showed significant results in multivariable but not in univariable analysis, 
whilst ESPOIR showed the reverse; it is unclear why this was the case.  
In this study, TtE was defined as “any pain or swelling”. This suggests some heterogeneity in 
the group categorisation, as swelling could have occurred later than pain, raising the issue 
of which type of pain without swelling led to the referral. Categorisation of the timeline 
between symptoms, swelling and TtE should decrease analysis bias. Also, as Leiden, quite 
logically, is conducting “at-risk of RA” studies, GPs have been offered guidance for early 
referral since 2013 (9), alerting them to the concept of “clinically significant arthralgia” (10). 
This may explain the big difference in RA diagnosis at first visit between the EAC (36%) and 
the ESPOIR cohort (78%).  Additionally, the large sample size with its’ statistical power 
should permit analysis of TtE as a continuous variable and define an optimal cut-off point 
(11). Also, it would be interesting to see if the large sample size could enable an internal 
cross-validation (12).  
The end-point of SDFR might have selected patients with a milder disease who were more 
likely to have a better outcome. Although, this was not supported by baseline data which 
showed the ≤6weeks TtE, compared to other TtE, had mostly equivalent measures of 
disease activity. Nevertheless, SDFR is a highly desirable outcome, and its prevalence in the 
Leiden cohort maybe partly due to the remission-induction trials undertaken in the 
Netherlands. Were the patients who achieved SDFR more likely to have had such 
treatment? If so, it could provide evidence that has been sought for so long, to support a 
more aggressive approach to early disease. Notwithstanding this, as SDFR is an extreme end 
point rarely achieved in routine practice, it would be very helpful to see the data of clinical 
remission on therapy, (say at 5 years) and for this end point the ESPOIR data representing 
routine clinical  practice (albeit with smaller numbers) could be more relevant for answering 
the role of TtE.  
 
What about radiology? Structural damage reduction, once the Holy Grail for 
rheumatologists, would have been expected to be observed in the early treated patients, 
especially as they had an improved outcome. However, there was little difference in 
radiological damage between the different TtEs. This lack of correlation between X-ray 
changes and SDFR suggests that in patients well treated early, the small level of structural 
damage becomes less important for outcome. 
 
This important study confirms the importance of rapid referral clinics and immediate 
therapy, if these findings are accepted, the implications are considerable. Seeing patients so 
rapidly is a logistics and cost challenge, but may be justified by a long-term health-economic 
analysis from a societal viewpoint. The study also raises the question of whether treating 
earlier could produce even better outcomes. To date, only one abstract has showed that 
individuals diagnosed with RA while being followed in an “at-risk” cohort had milder disease 
activity than those diagnosed through standard referral (13). Meanwhile, intervention 
studies in “at risk” populations which have so far looked at delaying/preventing clinical 
disease, may wish to focus more on SDFR once disease has occurred. 
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